Cardiovascular

FDA approves first implantable wireless device with remote monitoring to measure PAP in certain heart failure patients

On May 28, the U.S. Food and Drug Administration (FDA) approved the CardioMEMS HF System, which measures the pulmonary artery pressures (PAP) and heart rates of patients with New York Heart Association (NYHA) Class III heart failure who have been hospitalized for heart failure in the previous year. The device allows health care professionals to monitor patients remotely. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares